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Translational Relevance (147/120-150 words) 
This study evaluates the safety, pharmacokinetics, and clinical activity of patritumab, a fully human anti–
epidermal growth factor receptor 3 monoclonal antibody, in combination with cetuximab and a 
platinum agent for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head 
and neck (SCCHN). Preclinical data have shown in vitro and in vivo activity with patritumab plus 
cetuximab in SCCHN. Data in this study showed that in patients with SCCHN, patritumab plus cetuximab 
with a platinum-based therapy was tolerated with patritumab and cetuximab pharmacokinetic profiles 
similar to historical single-agent values. Favorable responses were observed with a tumor response rate 
(complete response + partial response) of 47%. Further, this study recommends an 18-mg/kg loading 
dose of patritumab, followed by a 9-mg/kg maintenance dose every 21 days.  These findings provide 
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preliminary evidence for the possible use of patritumab plus cetuximab with platinum as first-line 
therapy in SCCHN. 
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Abstract (250/250 words) 
Background: Patritumab plus cetuximab with platinum as first-line therapy for patients with recurrent 
and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) was evaluated for 
safety and to determine the recommended phase-II combination dose. 
Methods: Patients aged ≥18 years with confirmed R/M SCCHN received intravenous patritumab (18-
mg/kg loading dose [LD]); 9-mg/kg maintenance dose [MD] every 3 weeks [q3w]) + cetuximab (400-
mg/m2 LD; 250-mg/m2 MD weekly) + cisplatin (100 mg/m2 q3w) or carboplatin (area under the curve 
[AUC] of 5) for 6 cycles or until toxicity, disease progression, or withdrawal. Primary endpoints were 
dose-limiting toxicities (DLTs; grade ≥3 [21-day observation period]) and treatment-emergent adverse 
events (TEAEs). Pharmacokinetics, human antihuman antibodies (HAHA), tumor response, progression 
free survival (PFS), and overall survival (OS) were assessed. 
Results: Fifteen patients completed a median (range) of 8.7 (2.0-20.7) patritumab cycles. No DLTs were 
reported. Serious AEs were reported in 9 patients (patritumab-related n=4). TEAEs (N=15 patients) led to 
patritumab interruption in 7 patients. Patritumab-related dose reductions were reported in 1 patient. 
Patritumab (18 mg/kg) pharmacokinetics (N=15) showed mean (standard deviation) AUC0-21d of 2,619 
(560) µg∙day/mL and maximum concentration of 499.9 (90.4) µg/mL. All patients were HAHA-negative at 
study end (single, transient low titer in 1 patient). Tumor response rate (complete plus partial response; 
N=15) was 47%. Median (95% confidence interval) PFS and OS (N=15) were 7.9 (3.7-9.7) and 13.5 (6.6-
17.5) months, respectively. 
Conclusion: Patritumab (18-mg/kg LD, 9-mg/kg MD) plus cetuximab/platinum was tolerable, active in 
SCCHN, and was selected as the phase II dose-regimen.  
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INTRODUCTION 
Prognosis remains poor in patients with recurrent and/or metastatic (R/M) squamous cell carcinoma of 
the head and neck (SCCHN) (1); however, survival has improved with the use of cetuximab in this 
population (2−6). In patients treated in the first-line setting of R/M SCCHN, median progression-free 
survival (PFS) is approximately 4–6 months and median overall survival (OS) 10–15 months following 
first-line treatment with cetuximab in combination with chemotherapeutic agents (2−6). While 
cetuximab is effective in treating SCCHN, as well as colorectal cancer and non–small-cell lung cancer, 
many patients who initially respond, later develop resistance which limits efficacy (7,8). In cetuximab-
resistant SCHHN cell lines, targeting the human epidermal growth factor receptor (HER) family, including 
epidermal growth factor receptor (EGFR), HER2, and HER3, resulted in an inhibition of proliferation (9). 
 
Patritumab is a fully human anti–HER3 (HER3) monoclonal antibody that prevents heregulin-mediated 
HRG signaling by binding to the extracellular domain of HER3 (10)—thus inhibiting binding by the HER3 
ligand heregulin—and promoting receptor internalization and degradation (11). HER3 receives signals 
from ligands, most importantly from heregulin (12,13), the binding of which induces the conformational 
change necessary for receptor dimerization of HER3 with HER family receptors, such as EGFR or HER2 
(12−16).  
 
High expression of heregulin is associated with HER3 signaling (17), which has been shown to be 
important for tumor growth and proliferation, including in cell lines for non–small-cell lung cancer 
(NSCLC) (18) and SCCHN (19). Heregulin expression has been shown to be up-regulated in cisplatin-
resistant SCCHN cell lines (20).  When combined with EGFR inhibitors (including cetuximab and 
panitumumab) in NSCLC and SCCHN cell lines and mouse models, patritumab enhanced anti-tumor 
activity and prevented HER3 activation following anti-EGFR treatment (10,11,19). In a study by Wenzl et 
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al., synergistic effects of patritumab with cetuximab on signaling were observed in 70% (7/10) of 
patritumab-responsive SCCHN cell lines. Furthermore, the combination of patritumab and cetuximab 
resulted in a stronger inhibition of proliferation and induction of apoptosis compared to either 
treatment alone (19). In the same study, significant partial or even complete tumor reduction was 
demonstrated in a head and neck mouse xenograft model when patritumab was administered as a 
single agent and in combination with cetuximab or panitumumab, respectively. 
 
Given the evidence indicating enhanced in vitro and in vivo activity with patritumab plus cetuximab in 
SCCHN (19), combination therapy utilizing both targeted treatments may further improve efficacy in 
patients with R/M SCCHN. Therefore, in a phase Ib study, the safety and tolerability of first-line 
treatment with patritumab plus cetuximab with a platinum agent in patients with R/M SCCHN was 
investigated. Additionally, the recommended patritumab phase II dose was determined. The results of 
the phase Ib study are described herein.  
 
METHODS 
Overall study design 
This was a multi-center, open-label, single-arm study of first-line treatment of patritumab plus 
cetuximab with platinum-based therapy in patients with recurrent or metastatic SCCHN 
(clinicaltrials.gov identifier: NCT02350712). This study was conducted in compliance with the 
Declaration of Helsinki, the International Conference on Harmonization, Guideline for Good Clinical 
Practice, and applicable national and local regulatory requirements. The protocol was approved by the 
Institutional Review Board at each study site, and all patients provided written informed consent prior 
to participation in this study.  
 
8 
 
Patient eligibility 
Adults (age ≥18 years) with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; 
histologically or cytologically confirmed recurrent disease or metastatic SCCHN originating from the oral 
cavity, oropharynx, hypopharynx, and larynx; and with adequate hematological, renal, and hepatic 
function were eligible for inclusion in this study.   
 
Adequate hematologic function was defined as having an absolute neutrophil count ≥1.5 x 109/L, 
platelet count ≥100 x 109/L, and hemoglobin ≥10 g/dL. Adequate renal function was defined as having a 
calculated creatinine clearance ≥60 mL/minute. Adequate hepatic function was defined as having an 
aspartate aminotransferase and alanine aminotransferase ≤2.5 x upper limit of normal (ULN) (<5 x ULN 
if liver metastases are present), alkaline phosphatase ≤2.0 x ULN (<5 x ULN if bone or liver metastases 
are present), and bilirubin ≤1.5 x ULN. Patients also had prothrombin time or partial thromboplastin 
time ≤1.5 x ULN. Patients were to comply with the contraception requirements as specified in the study 
protocol or be of non-childbearing potential. 
 
Patients were excluded if they had prior anti-EGFR, anti-HER2, anti-HER3, or anti-HER4 targeted therapy, 
prior treatment for recurrent and/or metastatic disease, history of other malignancies, except 
adequately treated non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors 
curatively treated with no evidence of disease for ≥5 years, history of active brain metastases, left 
ventricular ejection fraction <50%, or uncontrolled hypertension (systolic blood pressure >160 mmHg or 
diastolic blood pressure >100 mmHg). 
 
Study objectives 
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The primary objectives were to evaluate the safety and tolerability of the combination of patritumab 
and cetuximab with cisplatin or carboplatin in the first-line treatment of patients with recurrent or 
metastatic SCCHN. An additional primary objective was to determine the recommended phase II dose 
for patritumab. 
 
Secondary objectives included characterization of the pharmacokinetics (PK) of patritumab and of 
cetuximab (when co-administered with patritumab) and evaluation of the incidence and titer of human 
anti-human antibody (HAHA) formation (anti-patritumab antibodies). Partial and complete response 
rates, PFS and OS were also assessed. 
 
Treatment 
All patients received intravenous patritumab (18-mg/kg loading dose; 9-mg/kg maintenance dose) every 
3 weeks plus cetuximab (400-mg/m2 loading dose; 250-mg/m2 maintenance dose) weekly plus cisplatin 
(100 mg/m2) every 3 weeks or carboplatin (area under the curve [AUC] of 5) for 6 cycles (Supplementary 
Fig. S1). The choice of platinum chemotherapy (cisplatin or carboplatin) was at the discretion of the 
investigator. Treatment cycles were 21 days, and patritumab and cetuximab could be continued beyond 
6 cycles. Treatment was continued until disease progression, evidence of toxicity, or withdrawal from 
the study. Patients were permitted to continue treatment in the extension phase of this study, which 
began after the recommended phase II dose was defined and all patients had completed platinum-
based treatment. 
 
Patritumab dose de-escalation 
 Six to 9 patients were expected to be treated at the first dose levels (fewer than 6 if 3 or more patients 
experienced a dose-limiting toxicity [DLT], in accordance with a 6+3 dose–de-escalation design). If ≤1 of 
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the first 6 DLT-evaluable patients experienced a DLT after all patients completed the DLT observation 
period (i.e., the first treatment cycle), the current dose of patritumab was defined as the maximum 
tolerated dose (MTD) and thus the recommended phase II dose. However, if 2 of the first 6 patients 
experienced a DLT, then the cohort was expanded to 9 patients at the same dose level; if 2 of those 9 
patients experienced a DLT, that current dose of patritumab was defined as the recommended phase II 
dose. If ≥3 patients experienced DLTs at any dose level, the MTD would have been exceeded and a lower 
patritumab loading dose (based on safety and PK data) could have been explored. If the patritumab 18 
mg/kg loading dose level was not tolerated based on observations of DLTs, for subsequent patients a 
lower loading dose of patritumab (15 mg/kg) and 9-mg/kg maintenance dose would have been 
administered in combination with cetuximab plus cisplatin or carboplatin every 3 weeks. 
 
The schedule of patritumab dosing was based on patient trough levels that corresponded to maximal 
preclinical efficacy, as measured in the phase I study of patritumab in patients with advanced solid 
tumors. (21) Patritumab also had a favorable tolerability profile as a single agent in solid tumors (21) and 
when combined with erlotinib in a phase I study of NSCLC. (22) In the phase I combination NSCLC study, 
with the exception of a slightly higher incidence of any grade treatment-emergent adverse events 
(TEAEs), such as diarrhea, the types of TEAEs and incidence of grade ≥3 AEs observed were generally 
similar (22) to those observed in a phase II study of erlotinib monotherapy (23). Therefore, there was 
supporting rationale that the starting schedule would be well tolerated and provide adequate exposure, 
and hence a dose de-escalation design was selected that would minimize exposing patients to 
potentially sub-therapeutic levels of patritumab. 
 
Study endpoints 
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Primary endpoints included evaluation of the incidence of DLTs (used to identify the MTD); the number 
of patients reporting the frequency and severity of TEAEs; the safety and tolerability of the combination 
of patritumab plus cetuximab and cisplatin or carboplatin; and the number of patients experiencing 
clinically significant or grade ≥3 changes in clinical laboratory evaluations, electrocardiograms, 
echocardiograms, vital signs, and physical examinations. 
 
Secondary endpoints included PK of serum patritumab and cetuximab, and the incidence and titer of 
HAHA formation. Other endpoints included tumor response, and PFS and OS. 
 
Study assessments 
Assessments occurred at predefined timepoints throughout the study, as described in Supplementary 
Table S1. Adverse events (AEs), including TEAEs and serious AEs (SAEs) were assessed per Common 
Terminology Criteria for Adverse Events (CTCAE; Version 4.03) and the Medical Dictionary for Regulatory 
Activities (Version 17.0). DLTs were defined as any patritumab-related grade ≥3 hematological or non-
hematological toxicity occurring during the DLT observation period (days 1–21), unless clearly attributed 
to causes other than patritumab treatment (not including alopecia, anorexia, fatigue [grade 1 or 2], and 
nausea and vomiting in absence of standard anti-emetic therapy). PK assessments of serum patritumab 
and cetuximab included the AUC from days 0–21 (AUC0–21), AUC from days 0 to infinity (AUC0–inf), half-life 
(T1/2), maximum concentration (Cmax), and time to maximum concentration (Tmax). Tumor response (i.e., 
complete response, partial response, stable disease, and progressive disease) was assessed via Response 
Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. PFS was defined as the time from the treatment 
start date to the date of the first radiographic disease progression or death due to any cause. OS was 
defined as the time from treatment start date to death from any cause. 
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Patients who discontinued the study for any reason were followed for 40 days after their last dose to 
assess the presence of HAHA and other AEs. Any patients who were positive for neutralizing antibodies 
required follow-up testing every 3 months for up to 1 year following the last dose and until titers 
returned to baseline or until the start of another cancer therapy. 
 
Statistical considerations and analysis 
The total sample size was not based on formal statistical power calculations; sample size was dependent 
on the number of patritumab dose levels tested and observations of DLTs. The study was expected to 
enroll 6–18 DLT-evaluable subjects in accordance with a 6+3 dose de-escalation design. The number of 
DLTs among the DLT-evaluable subjects were summarized for each dose of patritumab evaluated in 
combination with cetuximab plus cisplatin or carboplatin. Safety analyses were descriptive and 
presented in tabular format with the appropriate summary statistics. Serum concentrations for 
patritumab and cetuximab and PK parameters were summarized with descriptive statistics. PFS and OS 
(analyzed ad hoc) and 95% CIs were estimated using Kaplan-Meier analysis. 
 
RESULTS 
Patient disposition 
Patients were recruited between December 2014 and November 2015. Of the 17 subjects screened, 15 
patients enrolled and initiated treatment (Supplementary Table S2). As of December 21, 2016, 9 of the 
15 patients had completed the study treatment per protocol and continued into the extension phase for 
treatment with patritumab plus cetuximab. Overall, 6 patients discontinued from the study treatment 
phase due to progressive disease per RECIST criteria (n=3), death (n=1; due to cardiac arrest, considered 
related to cetuximab and carboplatin), a serious adverse event (n=1; bowel perforation, resolved; 
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considered related to patritumab and cetuximab), and spinal surgery due to a collapsed disc (n=1; due to 
a prior work-related injury). 
 
Patient demographics and baseline characteristics 
Of the 15 patients treated and included in the study, the median (range) age was 53 (31–65) years with a 
median (range) time to diagnosis of R/M disease of 25.2 (4.9–133.4) months (Table 1). 
Most (93%, n=14) patients had tumor stage 3 or 4 SCCHN and an ECOG performance status of 1 (87%, 
n=13). The majority of patients had prior treatment with radiation therapy (93.3%, n=14) and 
induction/concomitant systemic cancer therapy (53%, n=8). 
 
Treatment exposure and DLTs 
The median (range) number of treatment cycles was 8.7 (2.0–20.7) for patritumab, 8.7 (2.0–20.7) for 
cetuximab, 4.5 (2.0–7.3) for carboplatin, and 6.3 (3.7–8.3) for cisplatin (Supplementary Table S3).  Over 
the course of the study, the cumulative median (range) dose was 5,339.7 (1,710.0–11,259.0) mg for 
patritumab, 10,442.5 (2,481.4–22,874.9) mg for cetuximab, 2695.0 (830.0–4,150.0) mg for carboplatin, 
and 960.0 (520.4–1,136.5) mg for cisplatin (Supplementary Table S3). No DLTs were reported. Thus, 
there was no need for an additional cohort at a de-escalated dose.  
 
Safety  
Treatment-emergent SAEs and TEAEs 
Treatment-emergent SAEs were reported in 9 (60%) patients overall; in 6 (40%) patients SAEs were 
CTCAE grade ≥3 (Table 2). SAEs were considered related to patritumab, cetuximab, cisplatin, or 
carboplatin in 27% (n=4), 33% (n=5), 20% (n=3), and 27% (n=4) of patients, respectively. CTCAE grade ≥3 
TEAEs were reported in all 15 patients (Table 3). TEAEs considered related to patritumab (Table 3), 
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cetuximab, cisplatin, or carboplatin were reported in 93% (n=14), 100% (n=15), 53% (n=8), and 67% 
(n=10) of patients, respectively. The most commonly reported TEAEs (any grade) overall (93% [n=14] of 
patients) or considered related to patritumab (73% [n=11] of patients) were skin and subcutaneous 
tissue disorders, the majority of which were considered to be CTCAE grade <3 in severity. TEAEs led to 
patritumab interruption in 7 (47%) patients, which was considered related to patritumab in 5 (33%) 
patients.  
 
TEAEs leading to patritumab dose interruption included grade 3 anemia, grade 3 hypokalemia, and 
grade 2 weight loss (occurring in 1 patient); grade 3 hypomagnesemia, grade 2 leukopenia, and grade 1 
neutropenia (occurring in a second patient); grade 4 acneiform rash, grade 3 aspiration pneumonia; 
grade 3 dehydration, grade 3 diarrhea, and grade 1 thrombocytopenia (occurring in a third, fourth, fifth, 
sixth, and seventh patient, respectively). 
 
Patritumab dose reduction was reported in 1 (7%) patient with unresolved grade 1 mucositis, and was 
considered related to patritumab, cetuximab, and cisplatin. 
 
Development of HAHAs 
All patients were HAHA-negative at study end; however, a single, transient positive result with a low 
titer (<1:10) was reported for 1 patient on day 1 of cycle 2. 
 
Pharmacokinetics 
All patients were included in the PK analysis set. PKs for loading doses of patritumab (18 mg/kg) and 
cetuximab (400 mg/m2) are shown in Supplementary Table S4. For patritumab, the mean (SD) AUC0-21, 
AUCinf, and Cmax were 2,619 (560) µg∙day/mL, 2,957 (720) µg∙day/mL and 499.9 (90.4) µg/mL, 
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respectively. The median (range) Tmax values were 2.8 (1.0–6.1) hours. The estimated mean (SD) T1/2 
values were 6.6 (2.1) days. For cetuximab, the mean (SD) AUC0-21, AUCinf, and Cmax were 706 (161) 
µg∙day/mL, 800 (259) µg∙day/mL, and 246.7 (48.3) µg/mL, respectively. The median (range) Tmax values 
were 2.6 (1.0–5.0) hours. The estimated mean (SD) T1/2 values 2.8 (0.4) days. 
 
At the end of cycle 1, day 1, mean (SD) patritumab concentration was 460.3 (75.9) µg/mL, remaining 
relatively stable through 6 hours post-infusion, decreasing to 352.6 (65.6) µg/mL at 24-hours, 295.1 
(62.5) µg/mL at 48-hours, and 125.0 (36.9) µg/mL at 168 hours post-infusion; by 480 hours, patritumab 
concentration decreased to 76.1 (119.4) µg/mL (Fig. 1A). During the same timeframe, mean (SD) 
cetuximab concentration was 195.8 (51.1) µg/mL at the end of the first infusion, increasing slightly over 
the next 6 hours, and then decreasing to 160.1 (32.0) µg/mL at 24 hours, 120.0 (29.2) µg/mL at 48 hours, 
and finally 40.9 (13.1) µg/mL at 168 hours post-infusion (Fig. 1B). 
 
Efficacy 
Tumor response 
The tumor response rate (complete response + partial response) for all 15 patients was 47%. (Fig. 2 and 
Supplementary Table S5). Overall, 3 (20%) patients had a complete response, 4 (27%) had a partial 
response, and 8 (53%) had stable disease. Duration of response ranged from 8.3 to 55.6 weeks for 
patients with complete and partial response. Duration of stable disease ranged from 5.6 to 47.6 weeks 
for patients with stable disease. 
 
The best (minimum) percent change in sum of diameters from baseline in target lesions for each patient 
is illustrated in Fig. 3. Of the 15 patients included in this study, the majority had local recurrence (n=11), 
3 patients had distant metastasis (n=1 lung, n=1 lung and mediastinum, n=1 liver), and 1 patient had 
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both local recurrence and distant metastasis (lymph node and lung). All 3 patients who had a complete 
response had locoregional recurrence. Of the patients who had a partial response, 2 had locoregional 
recurrence and 2 had distant metastasis. 
 
PFS and OS 
The median PFS for all patients was 7.9 (95% CI 3.7–9.7) months (Supplementary Table S5). When 
analyzed over time, the PFS rate (95% CI) at 3, 6, 9, and 12 months was 87% (54–96%), 55% (25–77%), 
39% (14–63%), and 8% (0.5–30%), respectively (Supplementary Fig. S2A).  
 
The median OS for all patients was 13.5 (95% CI 6.6-17.5) months (Supplementary Table S5). When 
analyzed over time, the OS rate (95% CI) at 6, 12, and 18 months was 93% (61–99%), 53% (26–74%), and 
27% (8–50%), respectively (Supplementary Fig. S2B). 
 
 
DISCUSSION 
Options are limited in patients with R/M SCCHN; however, data from preclinical and clinical studies 
indicate that patritumab, in combination with cetuximab, may have improved benefit, compared with 
individual agents alone. In this phase Ib study in patients with R/M SCCHN, treatment with patritumab 
plus cetuximab with platinum-based therapy was tolerated and manageable. No DLTs were reported, 
and dose reductions due to a patritumab-related TEAE were reported in only 1 patient. All patients 
remained HAHA-negative at the end of the study. The recommended phase II dose of patritumab, 
therefore, remains an 18-mg/kg loading dose, followed by a 9-mg/kg maintenance dose every 21 days.  
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When comparing the PK profile of patritumab and cetuximab with historical data the mean (SD) Cmax of 
cetuximab for the 400 mg/m2 dose in combination with patritumab (246.7 [48.3] µg/mL) was similar 
compared with the mean Cmax from published studies of cetuximab PK alone (205.0 [65.7] µg/mL) (24). 
In addition, the mean (SD) AUCinf of cetuximab in combination with patritumab (800.0 [259.0] 
µg•day/mL) was similar to the historical values (791.7 [325.1] µg·day/mL) (24). The mean (SD) Cmax of 
patritumab was 499.9 (90.4) µg/mL in this study, similar to historical mean (SD) Cmax of 539.7 (135.3) 
µg/mL for patritumab [Daiichi Sankyo, data on file]. The mean (SD) AUCinf of patritumab was 2,957 (720) 
µg/mL in this study, similar to historical mean (SD) AUCinf of 3,151.8 (796) µg/mL for patritumab [Daiichi 
Sankyo, data on file]. However, population PK analysis is needed to confirm similar exposure between 
studies since body weight, an important covariate on volume of distribution and clearance, may have 
different distributions across the populations. The observed mean (SD) T1/2 of patritumab (6.61 [2.12] 
days) was slightly shorter, but comparable to historical data (mean [SD] 8.98 [1.62] days) (25). Similarly, 
the mean (SD) T1/2 of cetuximab (2.8 [0.4] days [i.e., 67.2 [8.6] hours]) was shorter than data from 
Delgado et al of cetuximab alone (mean 4.4 [range 3.3–6.7] days at week 3) (26), and data reported in 
the cetuximab prescribing information (mean 4.8 [range 3.1–7.8] days) (27), but similar to data reported 
by Tan et al (mean 3.1 [SD 0.66] days following single 2-hour infusion) (24). 
 
A favorable tumor response was also observed in the current study. Overall, median PFS was 7.9 months 
for all patients with 20% of patients achieving a complete response and 47% achieving overall response. 
In comparison, in a phase III (5) and a phase II (28) study of patients with R/M SCCHN who were treated 
with cetuximab plus cisplatin, median PFS was 4.2 and 6.0 months and overall response was 26% and 
42%, respectively (CR was achieved by 5% of patients in the phase II study and not reported in the phase 
III study). The median OS of 13.5 months in this current small study population is potentially promising. 
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Preliminary data from the follow-up phase II trial (clinicaltrials.gov identifier: NCT02633800) was 
reported at the 2018 Annual Meeting of the American Society of Clinical Oncology (29).  
 
Limitations 
There are several limitations of this study. Notably, this study included a small group of selected (not 
random) and relatively young (range: 31–65 years) group of patients. Further, this was an open-label 
study with no comparator and, therefore, tumor responses may not be representative of all patients 
with relapsed/metastatic SCCHN. Also, whilst we recognize that SCCHN is a heterogeneous disease, the 
relatively small number of patients in this study preclude investigation of tumor response and safety by 
the major tumor subsites represented (ie, oral cavity, oropharynx, and larynx). The collection of 
biomarker samples was not required in this study. However, this was a phase Ib study evaluating the 
safety and tolerability of patritumab plus cetuximab and a platinum-based therapy and provides 
evidence for future clinical studies. 
 
Conclusions 
Overall, the combination of patritumab with cetuximab and platinum therapy was tolerated, active in 
patients with R/M SCCHN, and did not appear to have a significant effect on the PK of cetuximab based 
on the non-compartmental analysis. 
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Figure Legends 
 
Figure 1.  
A, Mean plasma concentration of patritumab (18 mg/kg loading dose), by time. B, Mean plasma 
concentration of cetumximab (400 mg/m2 loading dose), by time. 
 
Figure 2.  
Tumor response and treatment duration (swimmer plot). AE, adverse event; CR, complete response; PR, 
partial response. aIncludes neck (n=6), neck and lymph nodes (n=1), oral (n=1), tongue (n=1), tongue and 
oropharynx (n=1), tonsil and lymph node (n=1) tumors.  
bIncludes lung (n=1), lung and mediastinum (n=1), and liver (n=1) tumors. 
cIncludes lymph node and lung tumors (n=1). 
 
Figure 3.  
Best (minimum) percent change in sum of diameters from baseline in target lesions (safety analysis 
population). Dotted line represents response (-30) and disease progression (+20). aIncludes 1 patient 
with moderately differentiated squamous cell carcinoma of the supraglottis. CR, complete response; PR, 
partial response; SD, stable disease.  
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